scholarly journals REPORT OF A CASE OF ADVANCED BREAST CANCER WITH NO BONE METASTASIS COMPLICATED BY HUMORAL HYPERCALCEMIA OF MALIGNANCY

2006 ◽  
Vol 67 (10) ◽  
pp. 2324-2327
Author(s):  
Hideya TASHIRO ◽  
Kohjiro MASHINO ◽  
Kyuzoh FUJII ◽  
Hisanobu SAKATA
Keyword(s):  
Breast Cancer ◽  
Bone Metastasis ◽  
Advanced Breast Cancer ◽  
Advanced Breast ◽  
Humoral Hypercalcemia Of Malignancy ◽  
Hypercalcemia Of Malignancy ◽  
Humoral Hypercalcemia

Everolimus combined with endocrine therapy in advanced HR-positive, HER2-negative Chinese breast cancer patients: A retrospective study.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. e13023-e13023
Author(s):  
Xia-Bo Shen ◽  
Guang-Liang Li ◽  
Ya-Bing Zheng ◽  
Zhan-Hong Chen ◽  
Wen-Ming Cao ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Bone Metastasis ◽  
Advanced Breast Cancer ◽  
Cancer Patients ◽  
Endocrine Therapy ◽  
Advanced Breast ◽  
High Price ◽  
Breast Cancer Patients ◽  
Subgroup Analyses ◽  
Visceral Disease

e13023 Background: The Food and Drug Administration (FDA) approves the combination of everolimus and exemestane for the treatment of advanced breast cancer patients who are hormone-receptor (HR) positive but human epidermal growth factor receptor-2 (HER2) negative. However, there is little real-world data on the everolimus in Chinese breast cancer patients. Endocrine therapy is the main treatment for advanced HR-positive, HER2-negative breast cancer patients which includes aromatase inhibitor (AI) or fulvestrant. Drug resistance and subsequent treatment after endocrine therapy are some of the most clinical concerns. CDK4/6 inhibitors and HDAC inhibitors are poorly available due to high price, and combined everolimus therapy can be a non-ignorable choice for advanced HR-positive, HER2-negative breast cancer patients. Methods: We retrospectively collected the treatment information of advanced breast cancer patients treated with everolimus from 2013 to 2020 in Zhejiang Cancer Hospital. Kaplan–Meier analysis and Cox regression methods were used to calculate and compare the progression-free survival (PFS). Results: The study finally enrolled 84 patients meeting the requirement, and patients were postmenopausal or premenopausal while received ovarian function suppression. And 54 patients were in the everolimus+AI group, 30 patients were in the everolimus+fulvestrant group. The median PFS in all 84 patients was 6.87 months, and the median overall survival (OS) was 28.87 months. The DCR in all 84 patients was 76.2%, and the most common grade 3-4 adverse event is stomatitis which is similar to other previous studies. Subgroup analyses were further performed based on everolimus combined with AI/fulvestrant. Patients were well-balanced in clinical characteristics in the two groups. Everolimus combined with fulvestrant group showed no superior to everolimus combined with AI group, 5.77 vs. 7.97 months (HR, 1.56; 95% CI, 0.92-2.65, P = 0.0735). Subgroup analyses showed everolimus combined with AI groups was superior to Everolimus combined with fulvestrant groups in some subgroups: postmenopausal group (HR, 0.50; 95% CI, 0.26-0.98); without bone metastasis group (HR, 0.22; 95% CI, 0.06-0.80); lung or pleura metastasis group (HR, 0.35; 95% CI, 0.16-0.77); visceral disease group (HR, 0.37; 95% CI, 0.20-0.69); previous therapy lines ≥ 4 group (HR, 0.44; 95% CI, 0.22-0.87). Conclusions: Everolimus combined with fulvestrant is not superior to everolimus combined with AI in HR-positive, HER2-negative breast cancer patients. For postmenopausal patients, patients without bone metastasis, and patients with visceral disease, everolimus combined with AI is a better choice.

scholarly journals Bone Metastasis in Advanced Breast Cancer: Analysis of Gene Expression Microarray

2018 ◽  
Vol 18 (5) ◽  
pp. e1117-e1122 ◽  
Author(s):  
Irawan Cosphiadi ◽  
Tubagus D. Atmakusumah ◽  
Nurjati C. Siregar ◽  
Abdul Muthalib ◽  
Alida Harahap ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Gene Expression ◽  
Bone Metastasis ◽  
Advanced Breast Cancer ◽  
Advanced Breast ◽  
Gene Expression Microarray ◽  
Expression Microarray

scholarly journals Safety and Efficacy of Long-Term Zoledronic Acid in Advanced Breast Cancer with Bone Metastasis in South China

2020 ◽  
Vol 2020 ◽  
pp. 1-10
Author(s):  
Qianyu Wang ◽  
Guifang Guo ◽  
Zhaohui Ruan ◽  
Huijiao Cao ◽  
Ying Guo ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Zoledronic Acid ◽  
Bone Metastasis ◽  
Advanced Breast Cancer ◽  
Hearing Impairment ◽  
Advanced Breast ◽  
Short Term ◽  
Short Term Treatment ◽  
Cox Regression Analysis

Background. This retrospective study aimed to characterize the long-term (>24 months) safety profile of zoledronic acid (ZA). We aimed to investigate whether long-term ZA treatment had greater benefits than short-term treatment in patients from southern China with advanced breast cancer (ABC) with bone metastasis. Patients and Methods. A total of 566 metastatic breast cancer cases were included and divided into two groups according to the duration of ZA treatment. The included patients had at least one lytic bone lesion and had no skeletal-related events (SREs) prior to ZA therapy. The primary endpoint was to analyze the safety and long-term adverse effects, which covered osteonecrosis of jaws (ONJ), renal impairment, and hearing impairment. The second objective was to determine the efficacy of long-term ZA treatment by the incidence of SREs. Results. Fifteen patients were diagnosed with ONJ (2.7%): nine in the short-term group (3.1%) and six in the long-term group (2.2%, P = 0.606). Five cases (0.9%) had renal function impairment: two in the short-term group (0.7%) and four in the long-term group (1.1%, P = 0.676). One patient (0.2%) in the long-term group had hearing impairment after 23 months of ZA treatment (0.4%, P = 0.482). In total, 103 cases in the short-term group (35.2%) and 138 cases in long-term group (50.5%) developed SREs (P < 0.001). The mean annual SRE rate was 0.3 in the short-term group (range, 0–3.1) versus 0.2 in the long-term group (0–1.0, P = 0.269). Subgroup analysis suggested that cases with non-load-bearing bone involvement and those who received systematic anticancer therapy without chemotherapy might benefit from long-term ZA treatment. Cox regression analysis indicated poor performance status, and nonvisceral organ involvement predicted high risk for SRE. Conclusions. The extension of ZA treatment did not increase the long-term adverse events and reduced the annual incidence of SREs beyond 24 months. Although longer treatment of ZA over 24 months appeared to be safe, further prospective investigation is required.

scholarly journals Multiscale characterization of the mineral phase at skeletal sites of breast cancer metastasis

2017 ◽  
Vol 114 (40) ◽  
pp. 10542-10547 ◽  
Author(s):  
Frank He ◽  
Aaron E. Chiou ◽  
Hyun Chae Loh ◽  
Maureen Lynch ◽  
Bo Ri Seo ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Bone Metastasis ◽  
Tumor Cell ◽  
Advanced Breast Cancer ◽  
Cancer Metastasis ◽  
Metastatic Breast ◽  
Advanced Breast ◽  
Anatomical Location ◽  
Primary Tumors ◽  
Disease Free

Skeletal metastases, the leading cause of death in advanced breast cancer patients, depend on tumor cell interactions with the mineralized bone extracellular matrix. Bone mineral is largely composed of hydroxyapatite (HA) nanocrystals with physicochemical properties that vary significantly by anatomical location, age, and pathology. However, it remains unclear whether bone regions typically targeted by metastatic breast cancer feature distinct HA materials properties. Here we combined high-resolution X-ray scattering analysis with large-area Raman imaging, backscattered electron microscopy, histopathology, and microcomputed tomography to characterize HA in mouse models of advanced breast cancer in relevant skeletal locations. The proximal tibial metaphysis served as a common metastatic site in our studies; we identified that in disease-free bones this skeletal region contained smaller and less-oriented HA nanocrystals relative to ones that constitute the diaphysis. We further observed that osteolytic bone metastasis led to a decrease in HA nanocrystal size and perfection in remnant metaphyseal trabecular bone. Interestingly, in a model of localized breast cancer, metaphyseal HA nanocrystals were also smaller and less perfect than in corresponding bone in disease-free controls. Collectively, these results suggest that skeletal sites prone to tumor cell dissemination contain less-mature HA (i.e., smaller, less-perfect, and less-oriented crystals) and that primary tumors can further increase HA immaturity even before secondary tumor formation, mimicking alterations present during tibial metastasis. Engineered tumor models recapitulating these spatiotemporal dynamics will permit assessing the functional relevance of the detected changes to the progression and treatment of breast cancer bone metastasis.

Sign in / Sign up

Export Citation Format

Share Document